Compare Abeona Therapeutics Inc (ABEO) vs Illinois Tool Works Inc. (ITW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Illinois Tool Works Inc. — how do they compare? Abeona Therapeutics Inc trades at $6.78 (market cap $373.32M), while Illinois Tool Works Inc. trades at $265.81 (market cap $77.99B). The key difference: Illinois Tool Works Inc. is far larger — about 208.9× Abeona Therapeutics Inc's market cap, and Illinois Tool Works Inc. pays a 2.38% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | ITW | |
|---|---|---|
Market Cap | $373.32M | $77.99B |
Sector | Health | Industrials |
52-Week High | $7.23 | $299.60 |
52-Week Low | $4.17 | $241.07 |
Enterprise Value | $228.22M | $86.31B |
Dividend Yield | — | 2.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
ITW trades at $271.09, down 0.61% on the day, with a bullish technical signal from moving averages and ADX indicators. The company maintains strong profitability with a 19.32% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights product upgrades from its Miller Electric division and a declared quarterly dividend of $1.61.
Outlook remains positive with raised 2026 EPS guidance, though valuation ratios like P/E of 25.47 suggest premium pricing. Risks include high debt levels and sensitivity to industrial demand cycles. Analyst consensus price target of $284.50 implies modest upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Illinois Tool Works Inc.
Illinois Tool Works is a diversified global manufacturer that produces specialized industrial equipment, consumables, and related services. The firm operates 87 global divisions through seven distinct operating segments: automotive OEM, construction products, food equipment, specialty products, test/measurement and electronics, polymers and fluids, and welding. About half of its revenue comes from its operations in North America, with the remainder originating from international markets. ITW takes a bottom-up and decentralized approach to portfolio management, with the exception that each segment must apply its 80/20 operating process modeled on the Pareto principle.
Read more on ITW →
